MCID: MJR001
MIFTS: 70

Major Depressive Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Depressive Disorder

MalaCards integrated aliases for Major Depressive Disorder:

Name: Major Depressive Disorder 53 37 12 72 71 36 28 13 14 69
Seasonal Affective Disorder 53 12 72 24 71 51 40 14 69
Unipolar Depression 53 71 51 69
Single Major Depressive Episode 12 69
Major Depressive Disorder 1 53 69
Major Depressive Disorder 2 53 69
Winter Depression 12 69
Mdd 53 71
Sad 24 71
Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment 53
Major Depressive Disorder, Response to Citalopram Therapy in 53
Major Depressive Disorder with a Seasonal Pattern 24
Seasonal Affective Disorder, Susceptibility to 53
Unipolar Depression, Susceptibility to 53
Recurrent Major Depressive Episodes 69
Depression in a Seasonal Pattern 24
Affective Disorder, Seasonal 24
Recurrent Major Depression 12
Depressive Disorder, Major 41
Seasonal Mood Disorder 24
Depression; Seasonal 24
Seasonal Depression 24

Classifications:



Summaries for Major Depressive Disorder

MedlinePlus : 40 Seasonal affective disorder (SAD) is a type of depression that comes and goes with the seasons. It usually starts in the late fall and early winter and goes away during the spring and summer. Some people do have episodes of depression that start in the spring or summer, but that is a lot less common. Symptoms of SAD may include Sadness Gloomy outlook Feeling hopeless, worthless, and irritable Loss of interest or pleasure in activities you used to enjoy Low energy Difficulty sleeping or oversleeping Carbohydrate cravings and weight gain Thoughts of death or suicide SAD is more common in women, young people, and those who live far from the equator. You are also more likely to have SAD if you or your family members have depression. The exact causes of SAD are unknown. Researchers have found that people with SAD may have an imbalance of serotonin, a brain chemical that affects your mood. Their bodies also make too much melatonin, a hormone that regulates sleep, and not enough vitamin D. The main treatment for SAD is light therapy. The idea behind light therapy is to replace the sunshine that you miss during the fall and winter months. You sit in front of a light therapy box every morning to get daily exposure to bright, artificial light. But some people with SAD do not respond to light therapy alone. Antidepressant medicines and talk therapy can reduce SAD symptoms, either alone or combined with light therapy. NIH: National Institute of Mental Health

MalaCards based summary : Major Depressive Disorder, also known as seasonal affective disorder, is related to endogenous depression and anxiety, and has symptoms including depressive symptoms and mental and behavioral signs and symptoms. An important gene associated with Major Depressive Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Serotonergic synapse and Circadian entrainment. The drugs Angiotensin II and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 An endogenous depression that is characterized by an all-encompassing low mood accompanied by low self-esteem, and by loss of interest or pleasure in normally enjoyable activities.

Genetics Home Reference : 24 Seasonal affective disorder is a mental health condition that is triggered by the changing of the seasons. This condition is a subtype of major depressive disorder and bipolar disorder. Major depressive disorder is characterized by prolonged sadness and a general lack of interest, while bipolar disorder is characterized by similar depressive episodes alternating with periods of abnormally high energy and activity (hypomania or mania). People with seasonal affective disorder have signs and symptoms of either major depressive disorder or bipolar disorder only during certain months of the year. Major depressive disorder is more common than bipolar disorder among people with seasonal affective disorder. This condition usually begins in a person's twenties or thirties.

UniProtKB/Swiss-Prot : 71 Major depressive disorder: A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning.

Wikipedia : 72 Major depressive disorder (MDD), also known simply as depression, is a mental disorder characterized by... more...

Description from OMIM: 608516

Related Diseases for Major Depressive Disorder

Diseases in the Major Depressive Disorder family:

Major Depressive Disorder 1 Major Depressive Disorder 2

Diseases related to Major Depressive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 endogenous depression 32.8 BDNF CHRM2 CRH HTR1A HTR2A MAOA
2 anxiety 32.6 BDNF CRH CYP2D6 HTR1A HTR2A HTR2C
3 mental depression 31.8 BDNF CRH CYP2D6 FKBP5 HTR1A HTR2A
4 generalized anxiety disorder 31.7 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
5 panic disorder 31.3 BDNF CRH HTR1A HTR2A HTR2C MAOA
6 dysthymic disorder 31.3 HTR2A MAOA SLC6A4
7 bipolar i disorder 31.2 BDNF HTR1A HTR2A HTR2C SLC6A4
8 schizophrenia 31.2 BDNF CYP2D6 DRD3 DRD4 HTR1A HTR2A
9 bipolar disorder 31.0 BDNF CLOCK CRH DRD3 DRD4 HTR1A
10 personality disorder 31.0 BDNF DRD3 DRD4 HTR1A HTR2A HTR2C
11 tardive dyskinesia 30.9 CYP2D6 DRD3 HTR2A
12 borderline personality disorder 30.9 BDNF FKBP5 HTR1A HTR2A HTR2C MAOA
13 tobacco addiction 30.8 HTR2A MAOA TPH1
14 post-traumatic stress disorder 30.8 BDNF CRH FKBP5 HTR2A MAOA SLC6A4
15 mood disorder 30.7 BDNF CLOCK CRH DRD4 HTR1A HTR2A
16 bulimia nervosa 2 30.7 BDNF CRH HTR2A SLC6A4
17 eating disorder 30.7 BDNF HTR2C SLC6A4
18 postpartum depression 30.7 BDNF CRH HTR1A MAOA SLC6A4
19 conduct disorder 30.7 DRD4 MAOA SLC6A4 TPH1
20 chronic fatigue syndrome 30.7 CRH HTR1A MAOA SLC6A4 TPH2
21 alcohol dependence 30.6 BDNF CHRM2 DRD3 DRD4 HTR1A HTR2A
22 kleptomania 30.5 HTR1A MAOA SLC6A4
23 paranoid schizophrenia 30.5 BDNF HTR2A MAOA SLC6A4 TPH2
24 agoraphobia 30.5 HTR1A MAOA SLC6A4
25 obsessive-compulsive disorder 30.5 BDNF CYP2D6 DRD3 DRD4 HTR1A HTR2A
26 schizoaffective disorder 30.5 BDNF DRD3 HTR2A SLC6A4
27 migraine with or without aura 1 30.3 CYP2D6 DRD3 DRD4 HTR1A HTR2A HTR2C
28 delusional disorder 30.2 DRD3 DRD4
29 attention deficit-hyperactivity disorder 30.1 BDNF CLOCK CYP2D6 DRD3 DRD4 HTR1A
30 restless legs syndrome 30.0 CLOCK DRD3 MAOA
31 social phobia 29.9 MAOA SLC6A4
32 major depressive disorder 1 12.3
33 major depressive disorder 2 12.3
34 mal de debarquement syndrome 11.8
35 sudden arrhythmia death syndrome 11.5
36 mitochondrial dna depletion syndrome 4a 11.1
37 psychosexual disorder 10.7 HTR1A HTR2A HTR2C SLC6A4
38 phobic disorder 10.7 HTR1A MAOA SLC6A4
39 bulimia nervosa 1 10.7 BDNF HTR2A MAOA SLC6A4
40 periodic limb movement disorder 10.7 HTR1A HTR2A HTR2C SLC6A4
41 alzheimer disease 5 10.7 HTR2A SLC6A4
42 schizophrenia 5 10.7 HTR1A HTR2A
43 brunner syndrome 10.7 HTR1A MAOA SLC6A4 TPH1
44 atypical depressive disorder 10.7 CRH MAOA SLC6A4
45 premature ejaculation 10.7 HTR1A HTR2C SLC6A4
46 schizoid personality disorder 10.7 HTR1A HTR2A
47 tic disorder 10.7 DRD4 HTR2A TPH2
48 oppositional defiant disorder 10.7 DRD4 MAOA SLC6A4 TPH2
49 hypoactive sexual desire disorder 10.7 HTR1A HTR2A
50 substance-induced psychosis 10.7 HTR1A HTR2A

Comorbidity relations with Major Depressive Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Acute Cystitis Adjustment Disorder
Alcohol Abuse Alzheimer Disease
Anxiety Atypical Depressive Disorder
Avoidant Personality Disorder Bipolar Disorder
Borderline Personality Disorder Bronchitis
Bulimia Nervosa 2 Cerebral Atherosclerosis
Cerebral Degeneration Chronic Myocardial Ischemia
Conversion Disorder Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dysthymic Disorder
Eating Disorder Esophagitis
Generalized Anxiety Disorder Heart Disease
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Major Affective Disorder 9
Mitral Valve Disease Mood Disorder
Narcissistic Personality Disorder Obsessive-Compulsive Disorder
Obsessive-Compulsive Personality Disorder Opioid Addiction
Osteoarthritis Osteoporosis
Paralytic Ileus Paranoid Personality Disorder
Paranoid Schizophrenia Parkinson Disease, Late-Onset
Personality Disorder Post-Traumatic Stress Disorder
Protein-Energy Malnutrition Respiratory Failure
Schizoid Personality Disorder Schizophrenia

Graphical network of the top 20 diseases related to Major Depressive Disorder:



Diseases related to Major Depressive Disorder

Symptoms & Phenotypes for Major Depressive Disorder

Clinical features from OMIM:

608516

UMLS symptoms related to Major Depressive Disorder:


depressive symptoms, mental and behavioral signs and symptoms

MGI Mouse Phenotypes related to Major Depressive Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 TPH2 BDNF CHRM2 CLOCK CRH DRD3
2 growth/size/body region MP:0005378 10.1 LRP8 NR1D1 PCLO SLC6A4 TPH1 TPH2
3 homeostasis/metabolism MP:0005376 10.1 TPH2 BDNF CHRM2 CLOCK CRH DRD3
4 cardiovascular system MP:0005385 10.02 SLC6A4 TPH1 TPH2 CHRM2 CLOCK DRD3
5 adipose tissue MP:0005375 9.98 CLOCK CRH DRD3 HTR2C NR1D1 TPH1
6 nervous system MP:0003631 9.8 BDNF CHRM2 CLOCK CRH DRD3 DRD4
7 integument MP:0010771 9.76 BDNF CHRM2 CLOCK CRH HTR2C SLC6A4
8 normal MP:0002873 9.23 BDNF CLOCK CRH FKBP5 LRP8 PCLO

Drugs & Therapeutics for Major Depressive Disorder

Drugs for Major Depressive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 577)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 54910-89-3 3386
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
5
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 5324346 3404
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 79617-96-2 68617
8
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34911-55-2, 34841-39-9 444
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-45-6, 75614-87-8 774
11
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
12
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85650-52-8, 61337-67-5 4205
13
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-41-2 439260
14
Trazodone Approved, Investigational Phase 4,Phase 3 19794-93-5 5533
15
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
16
Reboxetine Approved, Investigational Phase 4,Phase 2 71620-89-8, 98769-81-4 65856 123628
17
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
18
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
19
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927
20
Suvorexant Approved, Investigational Phase 4 1030377-33-3
21
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
22
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
23
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
24
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
25
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
26
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
27
Nortriptyline Approved Phase 4,Phase 1,Phase 2 72-69-5 4543
28
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
29
Trimipramine Approved Phase 4 739-71-9 5584 4055
30
Milnacipran Approved, Investigational Phase 4,Phase 3,Phase 2 92623-85-3 65833
31
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
32
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
33
Remifentanil Approved Phase 4 132875-61-7 60815
34
Tranylcypromine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 155-09-9 441233
35
Imipramine Approved Phase 4 50-49-7 3696
36
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
37
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
39
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
40
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 89594 942
41
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-23-7 657311 5754
42
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10118-90-8 5281021
43
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 2078-54-8 4943
44
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
45
Methylphenidate Approved, Investigational Phase 4,Phase 3 20748-11-2, 113-45-1 4158
46
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
47
Tibolone Approved, Investigational Phase 4,Phase 1 5630-53-5
48
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 508233-74-7 9966051
49
Tianeptine Approved, Investigational Phase 4 66981-73-5, 72797-41-2, 26638-66-4 68870 3075702
50
Selegiline Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1 14611-51-9 5195 26757

Interventional clinical trials:

(show top 50) (show all 2180)

# Name Status NCT ID Phase Drugs
1 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
2 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
3 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
4 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
5 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
6 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
7 Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder Unknown status NCT01696617 Phase 4 Aripiprazole 6-week group;Aripiprazole 8-week group
8 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
9 Lexapro®'s Efficacy After Dose Escalation in Remission Study Unknown status NCT01594866 Phase 4 escitalopram;escitalopram
10 Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder Unknown status NCT02129751 Phase 4 bupropion hydrobromide;Placebo
11 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
12 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
13 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
14 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
15 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
16 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
17 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
18 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
19 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
20 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
21 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
22 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
23 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
24 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
25 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
26 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
27 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
28 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
29 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
30 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
31 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
32 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
33 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
34 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
35 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
36 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
37 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
38 The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy Unknown status NCT02271555 Phase 4 Sevoflurane;Remifentanil;Saline
39 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
40 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
41 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
42 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4 Tranylcypromine
43 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
44 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01573598 Phase 4 Placebo;Vilazodone;Vilazodone
45 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01473381 Phase 4 Vilazodone;Placebo to citalopram;Placebo to vilazodone;Citalopram
46 Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder Completed NCT01473394 Phase 4 Dose-matched placebo;Vilazodone
47 Effects of Treatment on Decision-making in Major Depression Completed NCT01916824 Phase 4 Any FDA Approved Antidepressant
48 Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder Completed NCT01148472 Phase 4 Escitalopram;Duloxetine
49 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)
50 Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder Completed NCT01198795 Phase 4 Escitalopram

Search NIH Clinical Center for Major Depressive Disorder

Cochrane evidence based reviews: depressive disorder, major

Genetic Tests for Major Depressive Disorder

Genetic tests related to Major Depressive Disorder:

# Genetic test Affiliating Genes
1 Major Depressive Disorder 28 FKBP5 HTR2A TPH2

Anatomical Context for Major Depressive Disorder

MalaCards organs/tissues related to Major Depressive Disorder:

38
Brain, Testes, Heart, Cortex, Prefrontal Cortex, Pituitary, Amygdala

Publications for Major Depressive Disorder

Articles related to Major Depressive Disorder:

(show top 50) (show all 1166)
# Title Authors Year
1
Depression With Mixed Features in Major Depressive Disorder: A New Diagnosis or There All Along? ( 29419949 )
2018
2
A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder. ( 29409976 )
2018
3
Major depressive disorder: Longitudinal analysis of impact on clinical and behavioural outcomes in Uganda. ( 29424787 )
2018
4
Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: Possible association with major depressive disorder? ( 29414551 )
2018
5
Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment. ( 29407535 )
2018
6
Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study. ( 29433063 )
2018
7
In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes. ( 29441491 )
2018
8
Patterns of co-occurring addictions, posttraumatic stress disorder, and major depressive disorder in detoxification treatment seekers: Implications for improving detoxification treatment outcomes. ( 29415850 )
2018
9
Functional brain abnormalities in major depressive disorder using the Hilbert-Huang transform. ( 29427063 )
2018
10
Altered spontaneous brain activity in MRI-negative refractory temporal lobe epilepsy patients with major depressive disorder: A resting-state fMRI study. ( 29406962 )
2018
11
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. ( 29450462 )
2018
12
Plasma AI^ analysis using magnetically-labeled immunoassays and PET<sup>18</sup>F-florbetapir binding in non-demented patients with major depressive disorder. ( 29426824 )
2018
13
Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. ( 29432299 )
2018
14
Increased plasma nesfatin-1 levels may be associated with corticosterone, IL-6, and CRP levels in patients with major depressive disorder. ( 29427582 )
2018
15
MicroRNA132 associated multimodal neuroimaging patterns in unmedicated major depressive disorder. ( 29408968 )
2018
16
Association between increased serum interleukin-6 levels and sustained attention deficits in patients with major depressive disorder. ( 29415791 )
2018
17
Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. ( 29451287 )
2018
18
The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. ( 29414128 )
2018
19
Facial Emotion Recognition Performance Differentiates Between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder. ( 29360290 )
2018
20
Liquid chromatography/mass spectrometry-based plasma metabolic profiling study of escitalopram in subjects with major depressive disorder. ( 29448310 )
2018
21
Symptomatic and Functional Recovery From Major Depressive Disorder in the Ibadan Study of Ageing. ( 29426606 )
2018
22
Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study. ( 29407721 )
2018
23
Methylation Status of the Serotonin Transporter Promoter CpG Island Is Associated With Major Depressive Disorder in Chinese Han Population: A Case-Control Study. ( 27668354 )
2017
24
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
25
The sex-dependent role of the glucocorticoid receptor in depression: variations in the NR3C1 gene are associated with major depressive disorder in women but not in men. ( 27549215 )
2017
26
The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. ( 28144920 )
2017
27
[Characterisation of three polymorphisms of the tryptophan hydroxylase 2 gene in a sample of Colombian population with major depressive disorder]. ( 28193370 )
2017
28
Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. ( 28941119 )
2017
29
A genetic variant in miRNA binding site of glutamate receptor 4, metabotropic (GRM4) is associated with increased risk of major depressive disorder. ( 27792966 )
2017
30
Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. ( 28079463 )
2017
31
Interaction of estrogen receptor I^ and negative life events in susceptibility to major depressive disorder in a Chinese Han female population. ( 27814959 )
2017
32
Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. ( 27838145 )
2017
33
Intergenic variants may predispose to major depression disorder through regulation of long non-coding RNA expression. ( 27940106 )
2017
34
Resequencing three candidate genes discovers seven potentially deleterious variants susceptibility to major depressive disorder and suicide attempts in Chinese. ( 27964944 )
2017
35
A Combined Pathway and Regional Heritability Analysis Indicates NETRIN1 Pathway Is Associated With Major Depressive Disorder. ( 27422368 )
2017
36
Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence. ( 28813562 )
2017
37
Comparing the Profile of Temperament and Character Dimensions in Patients with Major Depressive Disorder and Bipolar Mood Disorder with a Control Group. ( 29062365 )
2017
38
Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR. ( 28638109 )
2017
39
Baclofen Abuse due to Its Hypomanic Effect in Patients with Alcohol Dependence and Comorbid Major Depressive Disorder. ( 28449569 )
2017
40
PRKCDBP (CAVIN3) and CRY2 associate with major depressive disorder. ( 27721187 )
2017
41
Combined Oral Contraceptive Pill Initiation in a Patient With Major Depressive Disorder, Premenstrual Dysphoric Disorder, Social Anxiety, Panic Disorder, and Histrionic Personality Disorder. ( 28638292 )
2017
42
Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa. ( 28469875 )
2017
43
Polymorphism of ERK/PTPRR Genes in Major Depressive Disorder at Resting-State Brain Function. ( 28467119 )
2017
44
The gender-specific association of rs334558 in GSK3I^ with major depressive disorder. ( 28099358 )
2017
45
Association between HTR1B alleles and suicidal ideation in individuals with major depressive disorder. ( 28007644 )
2017
46
A pilot study on predictors of brainstem raphe abnormality in patients with major depressive disorder. ( 27888722 )
2017
47
Predictors of response to repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder. ( 28034451 )
2017
48
Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. ( 28529365 )
2017
49
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
50
Association between neuropeptide Y receptor Y2 promoter variant rs6857715 and major depressive disorder. ( 27584037 )
2017

Variations for Major Depressive Disorder

Expression for Major Depressive Disorder

Search GEO for disease gene expression data for Major Depressive Disorder.

Pathways for Major Depressive Disorder

Pathways related to Major Depressive Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Serotonergic synapse hsa04726

GO Terms for Major Depressive Disorder

Cellular components related to Major Depressive Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 CHRM2 DRD3 DRD4 HTR1A HTR2A HTR2C

Biological processes related to Major Depressive Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 rhythmic process GO:0048511 9.82 CLOCK DRD4 NR1D1
2 circadian regulation of gene expression GO:0032922 9.74 CLOCK DRD3 NR1D1
3 response to drug GO:0042493 9.73 CRH DRD3 HTR2A HTR2C LRP8 SLC6A4
4 positive regulation of fat cell differentiation GO:0045600 9.72 HTR2A HTR2C TPH1
5 social behavior GO:0035176 9.71 DRD3 DRD4 SLC6A4
6 cellular calcium ion homeostasis GO:0006874 9.67 DRD3 DRD4 HTR2A HTR2C
7 regulation of dopamine secretion GO:0014059 9.65 DRD3 HTR2A
8 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.65 HTR1A HTR2A
9 dopamine receptor signaling pathway GO:0007212 9.64 DRD3 DRD4
10 synaptic transmission, dopaminergic GO:0001963 9.64 CRH DRD3
11 vasoconstriction GO:0042310 9.63 HTR1A SLC6A4
12 negative regulation of protein secretion GO:0050709 9.63 DRD3 DRD4
13 behavioral fear response GO:0001662 9.63 DRD4 HTR1A HTR2C
14 positive regulation of kinase activity GO:0033674 9.62 DRD4 HTR2A
15 dopamine metabolic process GO:0042417 9.62 DRD3 DRD4
16 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD3 DRD4
17 regulation of dopamine metabolic process GO:0042053 9.61 DRD4 HTR1A
18 regulation of behavior GO:0050795 9.59 HTR1A HTR2A
19 aromatic amino acid family metabolic process GO:0009072 9.58 TPH1 TPH2
20 regulation of hormone secretion GO:0046883 9.56 HTR1A HTR2A
21 indolalkylamine biosynthetic process GO:0046219 9.52 TPH1 TPH2
22 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.51 HTR2A HTR2C
23 behavioral response to cocaine GO:0048148 9.5 DRD3 DRD4 HTR2A
24 serotonin biosynthetic process GO:0042427 9.49 TPH1 TPH2
25 response to histamine GO:0034776 9.48 DRD3 DRD4
26 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.43 HTR2A HTR2C
27 regulation of serotonin secretion GO:0014062 9.4 CRH HTR1A
28 circadian rhythm GO:0007623 9.35 CLOCK NR1D1 SLC6A4 TPH1 TPH2
29 behavior GO:0007610 9.33 HTR1A HTR2A HTR2C
30 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C
31 signal transduction GO:0007165 10.23 CHRM2 CLOCK CRH DRD3 DRD4 HTR1A
32 G-protein coupled receptor signaling pathway GO:0007186 10.14 CHRM2 CRH DRD3 DRD4 HTR1A HTR2A

Molecular functions related to Major Depressive Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.97 CHRM2 DRD3 DRD4 HTR1A HTR2A HTR2C
2 signal transducer activity GO:0004871 9.85 DRD3 DRD4 HTR1A HTR2A HTR2C
3 dopamine binding GO:0035240 9.51 DRD3 DRD4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD3 DRD4
6 neurotransmitter receptor activity GO:0030594 9.43 HTR1A HTR2A HTR2C
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.4 TPH1 TPH2
8 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2A HTR2C
9 G-protein coupled serotonin receptor activity GO:0004993 9.33 HTR1A HTR2A HTR2C
10 tryptophan 5-monooxygenase activity GO:0004510 9.32 TPH1 TPH2
11 serotonin binding GO:0051378 9.13 HTR1A HTR2A HTR2C
12 drug binding GO:0008144 9.1 CHRM2 CYP2D6 DRD3 DRD4 HTR2A HTR2C

Sources for Major Depressive Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA